Zobrazeno 71 - 80
of 150
pro vyhledávání: '"Sherko Kuemmel"'
Autor:
Keun Seok Lee, Louis W.C. Chow, Joohyuk Sohn, Debu Tripathy, Seock-Ah Im, Saúl Campos-Gómez, Mei Ching Liu, Paul Wheatley-Price, Aditya Bardia, K Govind Babu, Yen-Shen Lu, Rafael Villanueva Vazquez, Fabio Franke, Sara A. Hurvitz, Samit Hirawat, C. Germa, Gary Carlson, Kyung Hae Jung, I Diaz-Padilla, Young-Hyuck Im, Sherko Kuemmel, Nadia Harbeck, Gareth Hughes, Nagi S. El-Saghir, Michelino De Laurentiis, Marco Colleoni
Publikováno v:
The Lancet Oncology. 19:904-915
Background: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast canc
Autor:
A. Kohls, Hans-Peter Fischer, Ronald E. Kates, Matthias Christgen, Michael Braun, T. Reimer, Hans Heinrich Kreipe, Nadia Harbeck, Jochem Potenberg, Katja Krauss, E-M. Grischke, Andrea Stefek, Helmut Forstbauer, O Gluz, Doris Augustin, Ulrike Nitz, Claudia Schumacher, Johannes Schumacher, Cornelia Liedtke, Sherko Kuemmel, Rachel Wuerstlein
Publikováno v:
Annals of Oncology. 28:2768-2772
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with stro
Autor:
Matthias Christgen, Nadia Harbeck, Eva-Maria Grischke, Oleg Gluz, Rachel Wuerstlein, Ulrike Nitz, Monika Graeser, Christine Eulenburg, Christoph Uleer, Sherko Kuemmel, Maren Darsow, Helmut Forstbauer, Michael Braun, Kerstin Luedtke-Heckenkamp, Bahriye Aktas, Ronald E. Kates, Hans Kreipe, Jochem Potenberg, Katarzyna Jozwiak, Claudia Schumacher
Publikováno v:
Journal of Clinical Oncology. 39:504-504
504 Background: In HR+/HER2- N0-1 early BC, postmenopausal patients (pts) with RS™ > 25 and a substantial proportion of premenopausal pts seem to benefit from addition of adjuvant chemotherapy (CT) to endocrine therapy (ET). However, the magnitude
Autor:
Tanja Fehm, Hans Kreipe, Rachel Wuerstlein, Timo Schinkoethe, Ulrike Nitz, Matthias Christgen, Ronald E. Kates, Hans Neubauer, Sherko Kuemmel, Christian Schem, Lelia Bauer, Monika Graeser, Tom Degenhardt, Iris Scheffen, Nadia Harbeck, Oleg Gluz, Norbert Marschner
Publikováno v:
Journal of Clinical Oncology. 39:TPS598-TPS598
TPS598 Background: The WSG ADAPT trial program addresses the individualization of (neo)adj. decision-making in EBC. The ADAPT umbrella trial established early predictive molecular surrogate markers for response after a 3-wk endocrine treatment (ET) t
Autor:
Katarzyna Jozwiak, Helmut Forstbauer, Valery Volk, Eva-Maria Grischke, Claudia Schumacher, Christoph Uleer, Hans Kreipe, Michael Hauptmann, Oleg Gluz, Rachel Wuerstlein, John Hackmann, Michael Braun, Bahriye Aktas, Ulrike Nitz, Monika Graeser, Ronald E. Kates, Nadia Harbeck, Sherko Kuemmel, Cornelia Kolberg-Liedtke, Matthias Christgen, Friedrich Feuerhake, Mathias Warm
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored.MethodsMultiplexed immunohistochemistry wa
Autor:
Rachel Wuerstlein, Doris Augustin, Bahriye Aktas, Ronald E. Kates, F Lorenz-Salehi, Petra Krabisch, Benno Nuding, Wolfram Malter, Nadia Harbeck, Ulrike Nitz, Michael R. Clemens, Hans Kreipe, Marianne Just, Oleg Gluz, Toralf Reimer, Andrea Stefek, Calvin Chao, Matthias Christgen, Cornelia Liedtke, Sherko Kuemmel, Steven Shak
Publikováno v:
Breast Cancer Research and Treatment. 165:573-583
The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here
Autor:
Antonia Perelló, Shah-Jalal Sarker, Isabel Ruiz, Andreas Makris, Elisabeth Oelmann, Cheryl Lawrence, A.M. Brunt, Anne Kendall, Joohyuk Sohn, Atiyyah Moosa, Keun Seok Lee, Gia Nemsadze, Marta Ferreira, Julien Grenier, Stephen Chan, Javier Cortes, Patricia Marosics, Michael Schenker, Peter Schmid, Catherine Harper-Wynne, Christopher J. Shepherd, John Conibear, Aaron Prendergast, Sherko Kuemmel, Matthias Zaiss, Kelly Mousa, Carike Coetzee, Janet E. Brown, Károly Máhr, Sidharth Dubey, Hartmut Kristeleit, Cristina Saura
Publikováno v:
JAMA Oncol
Importance Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8d54221b1897791291965de5b98f83
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
Autor:
Yeon Hee Park, A. Wang, Sung Bae Kim, Peter Schmid, Sherene Loi, Eva Muñoz-Couselo, Theodoros Foukakis, Javier Cortes, Sherko Kuemmel, Joohyuk Sohn, Lina Yin, Rebecca Dent, Konstantinos Tryfonidis, Roberto Salgado, Vassiliki Karantza
Publikováno v:
SSRN Electronic Journal.
Background: The phase 1b KEYNOTE-173 study assessed the safety and preliminary antitumour activity of neoadjuvant chemotherapy plus pembrolizumab in locally advanced non-metastatic triple-negative breast cancer (TNBC). Methods: Six pembrolizumab plus
Autor:
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck
Publikováno v:
Breast Cancer Research and Treatment
Background The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b4a4e0c7f424a0aadc5353df8d3ace5
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85059841249
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85059841249
Autor:
Christoph Uleer, Bahriye Aktas, Sherko Kuemmel, Ronald E. Kates, Daniel Gebauer, Laia Paré, Cornelia Kolberg-Liedtke, Rachel Wuerstlein, Michael Braun, Eva-Maria Grischke, Oleg Gluz, E Pelz, John Hackmann, Nadia Harbeck, Helmut Forstbauer, Matthias Christgen, Ulrike Nitz, Aleix Prat, Claudia Schumacher, Hans Kreipe, Mathias Warm
Publikováno v:
International journal of cancerReferences. 146(1)
In the neoadjuvant WSG-ADAPT-TN trial, 12-week nab-paclitaxel + carboplatin (nab-pac/carbo) was highly effective and superior to nab-paclitaxel + gemcitabine (nab-pac/gem) in triple-negative breast cancer regarding pathological complete response (pCR